James E Utts Net Worth

The estimated Net Worth of James E Utts is at least $925 Thousand dollars as of 24 February 2005. James Utts owns over 17,000 units of Baxter International stock worth over $925,201 and over the last 20 years James sold BAX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

James Utts BAX stock SEC Form 4 insiders trading

James has made over 2 trades of the Baxter International stock since 2005, according to the Form 4 filled with the SEC. Most recently James exercised 8,592 units of BAX stock worth $142,541 on 27 April 2005.

The largest trade James's ever made was exercising 17,000 units of Baxter International stock on 24 February 2005 worth over $282,030. On average, James trades about 3,199 units every 8 days since 2004. As of 24 February 2005 James still owns at least 23,560 units of Baxter International stock.

You can see the complete history of James Utts stock trades at the bottom of the page.

What's James Utts's mailing address?

James's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60035.

Insiders trading at Baxter International

Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney, and Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.

What does Baxter International do?

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

Complete history of James Utts stock trades at Baxter International

Baxter International executives and stock owners

Baxter International executives and other stock owners filed with the SEC include:

• Jose Almeida,
  Chairman of the Board, President, Chief Executive Officer
• James Saccaro,
  Chief Financial Officer, Executive Vice President
• Jeanne Mason,
  Senior Vice President - Human Resources
• Giuseppe Accogli,
  Senior Vice President, President- America
• Sean Martin,
  Senior Vice President, General Counsel
• Cristiano Franzi,
  Senior Vice President and President, EMEA
• Jose E. Almeida,
  Chairman, Pres & CEO
• Cristiano Franzi,
  Sr. VP & Pres for EMEA
• Giuseppe Accogli,
  Exec. VP & COO
• James K. Saccaro,
  Exec. VP & CFO
• Sean B. W. Martin,
  Sr. VP & Gen. Counsel
• Thomas Stallkamp,
  Lead Independent Director
• Albert Stroucken,
  Independent Director
• Peter Hellman,
  Independent Director
• James Gavin,
  Independent Director
• Patricia Morrison,
  Independent Director
• Stephen Oesterle,
  Independent Director
• Amy Wendell,
  Independent Director
• John Forsyth,
  Independent Director
• Michael Mahoney,
  Independent Director
• Cathy Smith,
  Independent Director
• Thomas Chen,
  Independent Director
• Jacqueline Kunzler,
  Senior Vice President and Chief Quality Officer
• Andrew Frye,
  Senior Vice President and President, APAC
• Brian Stevens,
  Senior Vice President, Chief Accounting Officer, Controller
• David S. Rosenbloom,
  Sr. VP & Gen. Counsel
• Clare Trachtman,
  VP of Investor Relations
• Brian C. Stevens,
  Sr. VP, Chief Accounting Officer & Controller
• Wilber C. Boren IV,
  Pres of Advanced Surgery
• Andrew Frye,
  Sr. VP & Pres of APAC
• Jeanne K. Mason,
  Sr. VP of HR
• Stacey Eisen,
  Sr. VP of Global Communications
• Talvis P. Love,
  Sr. VP & Chief Information Officer
• David P. Scharf,
  Corporate Vice President
• Kees J Storm,
  Director
• Marcus Schabacker,
  CVP, Chief Scientific Officer
• Robert Felicelli,
  CVP, Quality
• Brik V Eyre,
  CVP, Hospital Products
• Carole J Uhrich,
  Director
• Paul Vibert,
  CVP, International
• Scott Pleau,
  CVP - Operations
• Caroline Karp,
  CVP, Controller
• Point Llc Loeb Daniel S Third,
  
• Christopher A. Toth,
  EVP,Group Pres, Kidney Care
• William A. Ii Ampofo,
  Director
• Steven Flynn,
  SVP, President, APAC
• Peter M Wilver,
  Director
• David Brent Shafer,
  Director
• Thomas J Jr Sabatino,
  Senior Vice President
• Yuan Chia Pei,
  Director
• Cheryl L White,
  Corporate Vice President
• Joy A Amundson,
  Corporate Vice President
• Jill M Schaaf,
  CVP, Renal
• Harry M Jansen Jr Kraemer,
  Chairman and
• Robert J. Hombach,
  Corporate Vice President & CFO
• James E Utts,
  Corporate Vice President
• Uma Chowdhry,
  Director
• Peter J Arduini,
  Corporate Vice President
• Bruce Mc Gillivray,
  Corporate Vice President
• Sebastian J Bufalino,
  Corporate Vice President
• Jean Luc Butel,
  Corporate Vice President
• James M Gatling,
  Corporate Vice President
• John C Moon,
  Corporate Vice President
• Salto Carlos Del,
  Senior Vice President
• Wayne T Hockmeyer,
  Director
• Joseph B Martin,
  Director
• Michael J Baughman,
  Corporate Vice President
• Steven J Meyer,
  Treasurer
• Michael J Tucker,
  Senior Vice President
• James R Hurley,
  Corporate Vice President
• Monroe E Trout,
  Director
• Thomas Fang Tyan Chen,
  Director
• Nevelle J Jeharajah,
  Corporate Vice President
• Robert M Davis,
  Corp. VP, CFO and Treasurer
• Jan Stern Reed,
  Corporate Secretary
• Thomas H Glanzmann,
  Senior Vice President
• Walter E Boomer,
  Director
• Gail D Fosler,
  Director
• Phillip L. Batchelor,
  Corporate Vice President
• Karenann K Terrell,
  Corporate Vice President
• Robert L Jr Parkinson,
  Chairman of the Board and
• Karen J May,
  Corporate Vice President
• Timothy P Lawrence,
  CVP, Operations
• Blake E Devitt,
  Director
• John J Greisch,
  Senior Vice President & CFO
• Munib Islam,
  Director
• Gregory P Young,
  Corporate Vice President
• Susan R Lichtenstein,
  Corporate Vice President,
• Lawrence T Gibbons,
  Corporate Vice President
• David F Drohan,
  Senior Vice President
• Fred L Turner,
  Director
• Norbert G Riedel,
  Corporate Vice President
• Brian P Anderson,
  Senior Vice President
• Ludwig Hantson,
  Corporate Vice President
• David S. Wilkes,
  Director
• Nancy M Schlichting,
  Director
• Joel T. Grade,
  EVP and CFO
• Alok Sonig,
  EVP,Group President, Pharma
• David S. Rosenbloom,
  EVP and General Counsel
• Heather Knight,
  EVP,Group Pres,Med Products
• Reazur Rasul,
  EVP,Group Pres, Healthcare
• Jeffrey A Craig,
  Director
• Stephen H Rusckowski,
  Director
• James W Borzi,
  EVP,Chief Supply Chain Officer